Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 23Sarcoma 4Other solid neoplasm 4Gastrointestinal 4CNS 4Tumor-Agnostic 3Dermatologic 3Other hematologic neoplasm 2Genitourinary 2Breast 2Lymphoid 1Head & Neck 1

Conditions

Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Neuroblastoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Liver Neoplasms 1Laryngeal Diseases 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × capmatinib × Gastrointestinal × Clear all
NCT06988475 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Novartis

Phase 1/2 Completed
89 enrolled 37 charts
Gastrointestinal

Liver Neoplasms

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡